Supplementary Table 2.
(a) Overall and stratified mean hormonal modification and (b) overall and stratified mean semen parameters modification over the follow-up
| 2a | Overall mean modification | Stratification for single AIs | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Testolactone (2 g/daily; 100–200 mg/daily) | Anastrozole (1 mg/daily) | Letrozole (2.5 mg/daily) | ||||||||||
| Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | |
| Testosterone (ng dl−1) | 320.1±98.2 | 475.6±60.3 | 155.5 (48.5) | 401.2±117.1 | 479.5±85.4 | 78.2 (19.5) | 266.5±20.2 | 454±43.5 | 187.5 (70.3) | 265±14.1 | 511±22.6 | 246.2 (92.8) |
| Clark and Sherins19, 1989, USA, (n=25) | ||||||||||||
| Pavlovich et al.21 2001, USA, (n=63) | ||||||||||||
| Raman and Schlegel22 2002, USA, (n=140) | ||||||||||||
| Saylam et al.23 2011, Turkey, (n=27) | ||||||||||||
| Gregoriou et al.24 2012, Greece, (n=29) | ||||||||||||
| Helo et al.26 2015, USA, (n=26) | ||||||||||||
| Shoshany et al.25 2017, USA, (n=86) | ||||||||||||
| T/E2 ratio | 7.4±1.6 | 24.1±10.1 | 16.7 (227.2) | 5.1±0.2 | 12.5±0.2 | 7.4 (143.6) | 7.9±1.2 | 23.3±7.7 | 15.3 (193.1) | 8.5±0.7 | 37.5±2.1 | 29 (341.1) |
| Pavlovich et al.21 2001, USA, (n=63) | ||||||||||||
| Raman and Schlegel22, 2002, USA, (n=140) | ||||||||||||
| Saylam et al.23 2011, Turkey, (n=27) | ||||||||||||
| Helo et al.26 2015, USA, (n=26) | ||||||||||||
| Shoshany et al.25 2017, USA, (n=86) | ||||||||||||
| Estradiol (pg ml−1) | 36.9±13.7 | 26.8±13.1 | −10 (−27.3) | 47.3±17.1 | 39.9±14.4 | −7.4 (−15.7) | 34.4±10.6 | 23±5.8 | −11.3 (−34.2) | 26.3±0.5 | 14.7±0.2 | −11.5 (−44.1) |
| Clark and Sherins19 1989, USA, (n=25) | ||||||||||||
| Pavlovich et al.21 2001, USA, (n=63) | ||||||||||||
| Raman and Schlegel22 2002, USA, (n=140) | ||||||||||||
| Saylam et al.23 2011, Turkey, (n=27) | ||||||||||||
| Gregoriou et al.24 2012, Greece, (n=29) | ||||||||||||
| Helo et al.26 2015, USA, (n=26) | ||||||||||||
| Shoshany et al.25 2017, USA, (n=86) | ||||||||||||
| 2b | Overall mean modification | Stratification for single AIs | ||||||||||
| Testolactone (2 g/daily; 100–200 mg/daily) | Anastrozole (1 mg/daily) | Letrozole (2.5 mg/daily) | ||||||||||
| Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | Baseline | After treatment | Δ value (%) | |
| Sperm concentration (×106 ml−1) | 7.9±5.4 | 17.2±8.1 | 9.2 (116.3) | 10.8±7.4 | 20.1±12.5 | 9.3 (86.1) | 5.1±0.5 | 14.3±1.7 | 9.2 (181.3) | NE | NE | NE |
| Pavlovich et al.21 2001, USA, (n=63) | ||||||||||||
| Raman and Schlegel22, 2002, USA, (n=140) | ||||||||||||
| Shoshany et al.25 2017, USA, (n=86) | ||||||||||||
| Sperm motility (%) | 18.6±12.4 | 27.4±12.5 | 8.7 (47) | 20.8±8.7 | 33.1±17.1 | 12.2 (58.6) | 29.7±15 | 32.7±9 | 3.1 (10.2) | 9.1±2.8 | 17.5±6.4 | 8.5 (95.2) |
| Pavlovich et al.21 2001, USA, (n=63) | ||||||||||||
| Raman and Schlegel22, 2002, USA, (n=140) | ||||||||||||
| Saylam et al.23 2010, Turkey, (n=27) | ||||||||||||
| Gregoriou et al.24 2012, Greece, (n=29) | ||||||||||||
| Shoshany et al.25 2017, USA, (n=86) | ||||||||||||
| Total sperm count (×106/ejaculated Vol.) | 4.6±2.4 | 7.9±2.3 | 3.2 (69.8) | NE | NE | NE | NE | NE | NE | 3.1±0.2 | 6.2±1.3 | 2.9 (92) |
| Clark and Sherins19, 1989, USA, (n=25) | ||||||||||||
| Saylam et al.23 2011, 2010, Turkey, (n=27) | ||||||||||||
| Gregoriou et al.24 2012, Greece, (n=29) | ||||||||||||
NE: not evaluable